Opko Health, Inc.
- Country
- 🇨🇱Chile
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 3.9K
- Market Cap
- -
- Website
- http://www.opko.com
Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01357421
- Locations
- 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01225666
- Locations
- 🇭🇺
Hetényi Géza Hospital and Out-Patient Clinic, 1st Department of Internal Medicine, Szolnok, Hungary
🇮🇱Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
🇭🇺Semmelweis University, 2nd Clinic of Internal Medicine, Budapest, Hungary
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT01219855
- Locations
- 🇺🇸
OPKO Health, Inc, Bannockburn, Illinois, United States
MOD-4023 Study in Healthy Male Volunteers
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01060722
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00934050
- Locations
- 🇺🇸
Innovative Clinical Concepts, Paducah, Kentucky, United States
🇺🇸Raleigh Neurology Associates, Raleigh, North Carolina, United States
🇺🇸Premiere Research Institute, West Palm Beach, Florida, United States
A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00834223
- Locations
- 🇩🇴
Centro Laser, Santo Domingo, Dominican Republic
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
- Conditions
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT00743002
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00722384
- Locations
- 🇺🇸
OPKO site, Morristown, New Jersey, United States
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 353
- Registration Number
- NCT00568776
- Locations
- 🇺🇸
Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Sunrise Clinical Research, Inc, Hollywood, Florida, United States
🇺🇸Upstate Clinical Research, LLC, Albany, New York, United States
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- OPKO Health, Inc.
- Registration Number
- NCT00557791